204 related articles for article (PubMed ID: 29752722)
1. A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem.
Zhang Y; Fu J; Shi Y; Peng S; Cai Y; Zhan X; Song N; Liu Y; Wang Z; Yu Y; Wang Y; Shi Q; Fu Y; Yuan K; Zhou N; Joshi R; Ichim TE; Min W
Int J Cancer; 2018 Oct; 143(8):2039-2052. PubMed ID: 29752722
[TBL] [Abstract][Full Text] [Related]
2. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity.
Zhang Y; Feng Y; Huang Y; Wang Y; Qiu L; Liu Y; Peng S; Li R; Kuang N; Shi Q; Shi Y; Chen Y; Joshi R; Wang Z; Yuan K; Min W
Front Immunol; 2020; 11():968. PubMed ID: 32582152
[No Abstract] [Full Text] [Related]
4. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.
Zheng X; Koropatnick J; Chen D; Velenosi T; Ling H; Zhang X; Jiang N; Navarro B; Ichim TE; Urquhart B; Min W
Int J Cancer; 2013 Feb; 132(4):967-77. PubMed ID: 22870862
[TBL] [Abstract][Full Text] [Related]
5. Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model.
Liu Y; Xu P; Liu H; Fang C; Guo H; Chen X; Tan M; Zhang Y; Min W
Int J Oncol; 2020 Aug; 57(2):587-597. PubMed ID: 32468023
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.
Ou X; Cai S; Liu P; Zeng J; He Y; Wu X; Du J
J Cancer Res Clin Oncol; 2008 May; 134(5):525-33. PubMed ID: 17909857
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.
Sioud M; Mobergslien A; Sæbøe-Larssen S
Methods Mol Biol; 2015; 1218():269-76. PubMed ID: 25319657
[TBL] [Abstract][Full Text] [Related]
8. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.
Sioud M; Saebøe-Larssen S; Hetland TE; Kaern J; Mobergslien A; Kvalheim G
Int J Oncol; 2013 Jul; 43(1):280-8. PubMed ID: 23620105
[TBL] [Abstract][Full Text] [Related]
9. The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy.
Endo R; Nakamura T; Kawakami K; Sato Y; Harashima H
Sci Rep; 2019 Aug; 9(1):11335. PubMed ID: 31383907
[TBL] [Abstract][Full Text] [Related]
10. IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion.
Liu M; Li Z; Yao W; Zeng X; Wang L; Cheng J; Ma B; Zhang R; Min W; Wang H
Mol Med Rep; 2020 Jan; 21(1):445-453. PubMed ID: 31746428
[TBL] [Abstract][Full Text] [Related]
11. Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase.
Flatekval GF; Sioud M
Immunology; 2009 Sep; 128(1 Suppl):e837-48. PubMed ID: 19740345
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors.
Sun QF; Zhao XN; Peng CL; Hao YT; Zhao YP; Jiang N; Xue H; Guo JZ; Yun CH; Cong B; Zhao XG
Oncol Rep; 2015 Nov; 34(5):2289-95. PubMed ID: 26323510
[TBL] [Abstract][Full Text] [Related]
13. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
Lemos H; Mohamed E; Huang L; Ou R; Pacholczyk G; Arbab AS; Munn D; Mellor AL
Cancer Res; 2016 Apr; 76(8):2076-81. PubMed ID: 26964621
[TBL] [Abstract][Full Text] [Related]
14. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.
Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW
Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156
[TBL] [Abstract][Full Text] [Related]
15. Engineering better immunotherapies via RNA interference.
Sioud M
Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
[TBL] [Abstract][Full Text] [Related]
16. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
17. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
18. Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy.
Qin Y; Rouatbi N; Wang JT; Baker R; Spicer J; Walters AA; Al-Jamal KT
J Control Release; 2024 May; 369():251-265. PubMed ID: 38493950
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
Holtzhausen A; Zhao F; Evans KS; Tsutsui M; Orabona C; Tyler DS; Hanks BA
Cancer Immunol Res; 2015 Sep; 3(9):1082-95. PubMed ID: 26041736
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells transfected with indoleamine 2,3-dioxygenase gene suppressed acute rejection of cardiac allograft.
Li C; Liu T; Zhao N; Zhu L; Wang P; Dai X
Int Immunopharmacol; 2016 Jul; 36():31-38. PubMed ID: 27107370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
